References 483% CONFIDENCEOverall confidence: 83%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better

The first entry is always the pin's source. Overall confidence is a weighted average of how firmly each reference supports the start and end times used above; a reference counts half as much for every 180 days older than the newest.

• [1]90%
  biospace.com/press-releases/eylea-hd-aflibercept-approved-by-fda-as-first-and-only-injectable-anti-vegf-with-dosing-intervals-up-to-5-months-for-wet-age-related-macular-degeneration-wamd-and-diabetic-macular-edema-dme

  biospace.com· Posted Oct 5, 2026· Starts Apr 2, 2026 ✓· 34% of score

  The GlobeNewswire release is datelined 'TARRYTOWN, N.Y., April 02, 2026 (GLOBE NEWSWIRE)' and says the FDA 'has approved the extension of dosing intervals for EYLEA HD up to every 20 weeks'.

• [2]80%
  FDA approves extended dosing intervals up to 20 weeks for EYLEA HD in wAMD and DME - Ophthalmology Times

  ophthalmologytimes.com· Added Oct 5, 2026· 34% of score

  Trade coverage; headline read (page date metadata was unreliable).^[1]

• [3]70%
  FDA approves Regeneron's Eylea HD for extended five-month dosing interval - AllSci

  allsci.com· Published Apr 3, 2026· 16% of score

  Headline and publish time read.^[1]

• [4]85%
  EYLEA HD approved by FDA - Regeneron investor site

  investor.regeneron.com· Published Apr 2, 2026· 16% of score

  Regeneron's own release URL (surfaced by search; blocked to curl).

Suggest a correction

Something missing or wrong? Say it in your own words: a link that backs this pin up, a different start or end date and why, or a fact it lacks or gets wrong. The AI checks it against this pin's sources, searches for better ones, and adds any page that backs you up. The pin's own sources still count most. A picture that shows something else, or shows it badly, is looked at too, and moved down or replaced.